OBESITYsym is a sophisticated quantitative systems pharmacology (QSP) model designed to assist pharmaceutical companies in the development and optimization of new weight loss drugs. It addresses a critical challenge in current weight loss therapies: patient adherence often suffers due to common side effects like nausea. By leveraging a single QSP model and existing clinical data, OBESITYsym enables drug developers to accurately predict drug efficacy for weight loss and the probability of associated nausea side effects. The software helps identify optimal dosing strategies that maximize weight loss while minimizing adverse effects, making it easier for patients to adhere to treatments as intended. This capability is crucial for developing drugs that can significantly impact public health by reducing issues related to excess weight, such as heart disease and Type 2 diabetes. OBESITYsym was developed and extensively validated with clinical data using the Thales QSP modeling platform. It includes SimPops, a feature that allows users to simulate the full range of clinical responses reported for currently available GLP-1 treatments, enabling predictions for single and combination treatment strategies. Furthermore, the model facilitates the exploration of mechanisms and modes of action for novel treatments and allows for direct comparison of new compounds against established market drugs like semaglutide, tirzepatide, and liraglutide. Users can also integrate their own clinical experience and data into the platform to further refine and optimize predictions.

Features & Benefits

• Drug Efficacy & Side Effect Prediction
  • Predicts drug efficacy for weight loss, the expected range of weight loss, and the probability of nausea side effects to optimize drug development.
• Optimized Dosing Strategies
  • Identifies dosing strategies that maximize weight loss while simultaneously minimizing nausea, enhancing patient adherence.
• Patient Variability & Tolerance Insights
  • Predicts the range of patient variability, identifies patients likely to develop tolerance, and indicates which patients should be monitored for down-titration for safety.
• Validated QSP Modeling Platform
  • Developed and extensively validated with clinical data, running on the robust Thales QSP modeling platform.
• SimPops Clinical Simulation
  • Allows simulation of the full range of clinical responses reported for GLP-1 treatments, enabling outcome predictions for single and combination treatment strategies.
• Novel Compound Comparison & Mechanism Exploration
  • Enables exploration of mechanisms and modes of action for new treatments and comparison of novel compound performance against existing market drugs.
• Data Integration for Enhanced Prediction
  • Users can feed in their existing clinical experience and data to further optimize and refine the model's predictions.